Abstract:Mutations in the gene lead to Duchenne muscular dystrophy, a severe X-linked neuromuscular disorder that manifests itself as young boys acquire motor functions. DMD is typically diagnosed at 2 to 4 years of age, but the absence of dystrophin negatively impacts muscle structure and function before overt symptoms appear in patients, which poses a serious challenge in the optimization of standards of care. In this report, we investigated the early consequences of dystrophin deficiency during skeletal muscle development. We used single-cell transcriptome profiling to characterize the myogenic trajectory of human pluripotent stem cells and showed that DMD cells bifurcate to an alternative branch when they reach the somite stage. Here, dystrophin deficiency was linked to marked dysregulations of cell junction protein families involved in the cell state transitions characteristic of embryonic somitogenesis. Altogether, this work demonstrates that , dystrophin deficiency has deleterious effects on cell-cell communication during myogenic development, which should be considered in future therapeutic strategies for DMD.

What problem does this paper attempt to address?

This paper aims to explore the impact of the lack of dystrophin on the early stages of embryonic skeletal muscle development in Duchenne Muscular Dystrophy (DMD). Specifically, the researchers used human - induced pluripotent stem cells (hiPSCs) to simulate the cell state of DMD patients and studied the changes of these cells during the differentiation into skeletal muscle cells through single - cell transcriptome analysis technology. The study found that when hiPSCs derived from DMD patients differentiated into the somite stage, they showed different differentiation trajectories compared with normal control cells, especially with significant abnormalities in the expression of the cell - junction protein family. These findings indicate that the lack of dystrophin can affect inter - cellular communication and coordinated migration, especially during somite formation, which may provide new insights into the pathogenesis of DMD and a reference for future treatment strategies. ### Research Background - **Disease Overview**: DMD is a severe X - linked neuromuscular disease that mainly affects boys and shows symptoms when they begin to acquire motor functions. The diagnosis of this disease is usually between 2 and 4 years old, but the deletion of dystrophin has already had a negative impact on muscle structure and function before the symptoms appear. - **Research Purpose**: The researchers hope to reveal the early pathological mechanism of DMD and provide a scientific basis for optimizing treatment standards by exploring the impact of the lack of dystrophin on skeletal muscle development during the embryonic period. ### Main Findings - **Differences in Cell Differentiation Trajectories**: Using single - cell transcriptome analysis technology, the researchers found that when hiPSCs of DMD patients differentiated into the somite stage, different differentiation paths emerged compared with normal cells. This indicates that the lack of dystrophin affects cell fate determination. - **Abnormal Expression of the Cell - Junction Protein Family**: DMD cells showed abnormal expressions of multiple cell - junction protein families at the somite stage, especially the down - regulation of tight - junction and desmosomal proteins, while some members of the protocadherin family were up - regulated. - **Impaired Cell - State Transition**: The study also found that the lack of dystrophin led to impaired cell - state transition during somite development, especially the transition from mesenchymal to epithelial and the subsequent epithelial - to - mesenchymal transition, which may have affected the colonization and migration of future muscle regions. ### Conclusion The research results show that the lack of dystrophin not only affects the function of mature muscle cells but also has an adverse effect in the early stages of embryonic skeletal muscle development, especially interfering with inter - cellular communication and coordinated migration. These findings provide important clues for understanding the early pathological mechanism of DMD and suggest that future treatment strategies should consider these early effects.

Dystrophin deficiency impairs cell junction formation during embryonic myogenesis

Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts

Uncovering the Embryonic Origins of Duchenne Muscular Dystrophy

Muscle stem cells in Duchenne muscular dystrophy exhibit molecular impairments and altered cell fate trajectories impacting regenerative capacity

Myopathologic trajectory in Duchenne muscular dystrophy (DMD) reveals lack of regeneration due to senescence in satellite cells

Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy

CRISPR/Cas9-Based Dystrophin Restoration Reveals a Novel Role for Dystrophin in Bioenergetics and Stress Resistance of Muscle Progenitors

Cellular pathogenesis of Duchenne muscular dystrophy: progressive myofibre degeneration, chronic inflammation, reactive myofibrosis and satellite cell dysfunction

Empowering Muscle Stem Cells for the Treatment of Duchenne Muscular Dystrophy

Duchenne muscular dystrophy: pathogenesis and promising therapies

Disease exacerbation by fibroblast inclusion in Duchenne Muscular Dystrophy MYOrganoids reveals limitations of microdystrophin therapeutic efficacy

Profound cellular defects attribute to muscular pathogenesis in the rhesus monkey model of Duchenne muscular dystrophy

Abstract 44: Telomere and Mitochondrial Dysfunction in Duchenne Muscular Dystrophy

DMD Human iPSC-derived skeletal muscle cells recapitulate selective calcium dysregulation pathways

Abstract 310: Mechanistic Insights into Duchenne Muscular Dystrophy-Associated Cardiomyopathy

Effects of Mini-Dystrophin on Dystrophin-Deficient, Human Skeletal Muscle-Derived Cells

Inhibiting EZH2 complements steroid effects in Duchenne muscular dystrophy

Expression of Dystrophin-Glycoprotein Complex at the Skeletal Muscle Sarcolemma in Duchenne Muscular Dystrophy

Defective satellite cells in congenital myotonic dystrophy

Cell transplantation-mediated dystrophin supplementation efficacy in Duchenne muscular dystrophy mouse motor function improvement demonstrated by enhanced skeletal muscle fatigue tolerance

Mechanisms of resistance to pathogenesis in muscular dystrophies